Sage Journals: Discover world-class research

Open access

Review article

First published 2022

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma

Omar Albanyan, Julio Chavez, Javier Munoz

Therapeutic Advances in Hematology

Retricted access

Review article

First published 2022-12

New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma

Donald C. Moore, Matthew R. Peery, Katherine A. Tobon [...]

Journal of Oncology Pharmacy Practice

Open access

Research article

First published 2013

Clinical Characteristics and Risk of Relapse for Patients with Stage I-II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy

S. Mercadal, F. Climent, E. Domingo-Doménech [...]

Blood & Plasma

Open access

Research article

First published 2026

Historic Real-World Outcomes and Future Benchmarks for Patients with Diffuse Large B-Cell Lymphoma Receiving First- and Second-Line Therapy in Austria – a Large Single-Center Experience

Michael Leisch, Dominik Kiem, Christoph Grabmer [...]

Technology in Cancer Research & Treatment

Open access

Research article

First published 2024-04

Real-World Outcomes of Adolescents and Young Adults with Diffuse Large B-Cell Lymphoma: A Multicenter Retrospective Cohort Study

Denisse Castro-Uriol, Ligia Rios, Daniel Enriquez-Vera [...]

Journal of Adolescent and Young Adult Oncology

Open access

Research article

First published 2023

Cost-effectiveness analysis of axicabtagene ciloleucel as a second-line treatment for diffuse large B-cell lymphoma in China and the United States

Na Li, Jianying Lei, Jiahao Zhang [...]

Therapeutic Advances in Hematology

Open access

Research article

First published 2025-1

A Cost-Effectiveness Analysis of Diffuse Large B-Cell Lymphoma Treatment Pathways in the United States

Anik R. Patel, Bradley Kievit, Ken Hasegawa [...]

MDM Policy & Practice

Retricted access

Research article

First published 2025

Descriptive analysis of the efficacity of R-GEMOX /R-IE/R-CEPP in patients with relapsed/refractory (R/R) transplant-ineligible diffuse large B-cell lymphoma (DLBCL)

Baptiste Fulbert, Théo Vincent, Justine Clarenne [...]

Journal of Oncology Pharmacy Practice

Search results